Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
Want to see CTNM full AI Analyst Report?
Top Page
Contineum Therapeutics, Inc. Class A
(NASDAQ:CTNM)
Select Model
Select Model
Rating:58Neutral
Price Target:
$12.00
▼(-11.31% Downside)
Action:Reiterated
Date:05/09/26
CTNM’s score is primarily constrained by weak financial performance (no recent revenue, sizable losses, and ongoing cash burn) despite a relatively strong, low-leverage balance sheet. Technicals are supportive with price above major moving averages and positive momentum indicators. Valuation is less favorable given negative earnings and no dividend yield, while recent corporate events add moderate support via positive early clinical data and pipeline/financing updates.
Positive Factors
Low leverage / balance sheet strength
Contineum’s very low leverage and sizable equity position provide durable financial flexibility to fund clinical programs and absorb trial delays without immediate refinancing. Over the next several months this reduces near-term solvency risk and preserves optionality for strategic partnerships or staged financings.
Negative Factors
No recent revenue and sustained operating losses
As a clinical-stage biotech without product revenue, Contineum’s operations are reliant on external capital while reporting substantial recurring losses. Over 2–6 months this structural lack of revenue constrains self-funding ability, heightens dependence on financings, and limits strategic flexibility compared with revenue-generating peers.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / balance sheet strength
Contineum’s very low leverage and sizable equity position provide durable financial flexibility to fund clinical programs and absorb trial delays without immediate refinancing. Over the next several months this reduces near-term solvency risk and preserves optionality for strategic partnerships or staged financings.
Read all positive factors
Contineum Therapeutics, Inc. Class A (CTNM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$461.35M
Dividend YieldN/A
Average Volume (3M)170.88K
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue GrowthN/A
EPS Growth-1.14%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.95
Shares Outstanding32,723,877
10 Day Avg. Volume105,448
30 Day Avg. Volume170,880
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.21
Price to Sales (P/S)0.00
P/FCF Ratio-5.70
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.03K
Enterprise Value/Ebitda-7.59
Forecast
1Y Price Target
$21.20Price Target Upside56.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$8.26M
Contineum Therapeutics, Inc. Class A Business Overview & Revenue Model
Company Description
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is ...
How the Company Makes Money
null...
Contineum Therapeutics, Inc. Class A Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 50.00M | 0.00 | 0.00 |
| Gross Profit | -162.00K | 0.00 | -258.00K | 50.00M | 0.00 | 0.00 |
| EBITDA | -64.75M | -67.74M | -42.00M | 23.57M | -23.54M | -28.34M |
| Net Income | -58.44M | -59.98M | -42.26M | 22.72M | -24.25M | -29.00M |
Balance Sheet | ||||||
| Total Assets | 261.35M | 276.64M | 212.85M | 130.39M | 50.64M | 70.52M |
| Cash, Cash Equivalents and Short-Term Investments | 246.33M | 262.90M | 204.76M | 125.19M | 47.24M | 69.00M |
| Total Debt | 6.95M | 8.25M | 6.26M | 193.19M | 5.85M | 4.91M |
| Total Liabilities | 11.31M | 15.65M | 14.78M | 198.32M | 11.37M | 8.93M |
| Stockholders Equity | 250.04M | 260.99M | 198.07M | -67.94M | 39.27M | 61.59M |
Cash Flow | ||||||
| Free Cash Flow | -57.66M | -55.54M | -33.36M | 18.93M | -20.24M | -26.43M |
| Operating Cash Flow | -57.17M | -55.31M | -32.84M | 19.35M | -20.12M | -26.27M |
| Investing Cash Flow | -57.94M | -3.71M | -69.74M | -65.57M | 22.30M | -64.97M |
| Financing Cash Flow | 112.79M | 112.69M | 109.00M | 56.18M | -1.24M | 79.84M |
Contineum Therapeutics, Inc. Class A Technical Analysis
Negative
13.53
Price Trends
13.26
Negative
13.60
Negative
12.42
Negative
Market Momentum
-0.33
Positive
33.95
Neutral
6.27
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTNM, the sentiment is Negative. The current price of 13.53 is above the 20-day moving average (MA) of 13.34, above the 50-day MA of 13.26, and above the 200-day MA of 12.42, indicating a bearish trend. The MACD of -0.33 indicates Positive momentum. The RSI at 33.95 is Neutral, neither overbought nor oversold. The STOCH value of 6.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTNM.
Contineum Therapeutics, Inc. Class A Risk Analysis
Contineum Therapeutics, Inc. Class A disclosed 78 risk factors in its most recent earnings report. Contineum Therapeutics, Inc. Class A reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Contineum Therapeutics, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $461.35M | -7.34 | -27.09% | ― | ― | -1.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.62B | -13.39 | -59.27% | ― | -100.00% | -62.96% | |
50 Neutral | $905.62M | -14.75 | -73.23% | ― | ― | -42.64% | |
50 Neutral | $289.84M | -3.45 | -0.11% | ― | ― | 40.79% | |
45 Neutral | $115.22M | -0.90 | -55.83% | ― | ― | -48.08% | |
42 Neutral | $28.89M | -1.76 | -64.17% | ― | -100.00% | 94.65% |
* Healthcare Sector Average
CTNM
Contineum Therapeutics, Inc. Class A
11.49
7.01
156.47%
TVRD
Tvardi Therapeutics
2.89
-24.01
-89.26%
CAPR
Capricor Therapeutics
26.71
13.33
99.63%
DRTS
Alpha Tau Medical Ltd
9.35
6.23
199.68%
IMRX
Immuneering
4.27
2.10
96.77%
ENGN
enGene Holdings
1.64
-1.71
-51.04%
Contineum Therapeutics, Inc. Class A Corporate Events
Business Operations and StrategyProduct-Related Announcements
Contineum Therapeutics Reports Positive Phase 1b Chronic Pain Data
Positive
Apr 30, 2026
On April 30, 2026, Contineum Therapeutics reported positive topline results from an exploratory Phase 1b trial of its non-opioid candidate PIPE-791 in patients with chronic osteoarthritis pain and chronic low back pain. PIPE-791, given orally at 1...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.